Dravet Syndrome Diet - Search News

Biogen, Dravet syndrome and Stoke

Biogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally

Biogen (NASDAQ:BIIB) and Stoke Therapeutics (NASDAQ:STOK) said on Tuesday they are collaborating to develop and commercialize zorevunersen, an investigational treatment for Dravet syndrome, in territories outside the United States,

Contract Pharma · 3d

Biogen, Stoke Partner on Zorevunersen in Dravet Syndrome

Biogen receives exclusive rights to commercialize zorevunersen outside U.S., Europe, and Japan.

MarketWatch · 4d

Biogen, Stoke Therapeutics Set Dravet Syndrome Collaboration

Biogen and Stoke Therapeutics have agreed to collaborate on Stoke's proposed zorevunersen treatment for the severe genetic epilepsy Dravet syndrome in a deal potentially worth hundreds of millions of dollars to Stoke.

STAT · 4d

Biogen partners with Stoke Therapeutics on drug for severe epilepsy

Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s experimental drug for Dravet syndrome, outside the U.S.

News Medical on MSN4d

Gene therapy breakthrough offers hope for severe Dravet syndrome cases

AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...

Nature2y

Harnessing the gut–immune–brain axis to treat disease

Hsiao and her collaborators showed that the diet changes the microbiome ... to treat drug-resistant seizures in patients with Dravet syndrome and other developmental and epileptic ...

FierceBiotech9d

Encoded lays off 29% of staff to fund Dravet syndrome gene therapy trial

Encoded Therapeutics is shrinking its headcount by 29% as the gene therapy biotech draws resources away from its early-stage ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Biogen, Dravet syndrome and Stoke

Trending now